Valeant gains Valeo's dermatology portfolio

26 August 2014 - Deborah Wilkes

Archived

Valeant Pharmaceuticals International has acquired a portfolio of dermatology products and several specialty pharmaceuticals from Canada's Valeo Pharma in a deal worth US$25.3 million.

Click tags below for more information on topics:

Bausch Health

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: